Literature DB >> 22290887

Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.

Naoko Ose1, Noriyoshi Sawabata, Masato Minami, Masayoshi Inoue, Yasushi Shintani, Yoshihisa Kadota, Meinoshin Okumura.   

Abstract

OBJECTIVES: Positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography (FDG-PET/CT) are utilized for the diagnosis of lymph node (LN) metastasis from lung cancer. In this study, we analyzed the diagnostic ability of FDG-PET for N staging by focusing on the clinical features of false-positive (FP) and false-negative (FN) cases.
METHODS: From March 2006 to February 2010, 112 patients underwent preoperative examinations using FDG-PET/CT followed by radical resection with hilar and mediastinal dissection. We analyzed their clinicopathological characteristics based on preoperative FDG-PET/CT findings and post-operative histopathological diagnosis of resected LNs.
RESULTS: Based on the PET/CT results, 17 patients were misdiagnosed (9 FN and 8 FP). The sensitivity, specificity, accuracy and negative and positive predictive values for N1/N2 were 50.0, 94.5, 84.0, 93.0 and 58.3%, respectively, whereas those for N2 were 57.8, 90.3, 84.8, 90.3 and 61.1%, respectively. FP findings more frequently occurred in cases with elevated white blood cell (WBC) count (P=0.015) and smokers (P=0.04). In the FN group, the maximum standardized uptake value for the primary tumour was lower than that in the true-positive (TP) group (P=0.01). The short-axis sizes of 71 LNs differently diagnosed by PET/CT and histopathology findings were significantly smaller in the FN group than the TP group (P<0.001), whereas there was no difference between TP and FP. As for FN LNs in the TP group, there was no significant difference.
CONCLUSIONS: PET/CT showed a good ability to detect metastatic LNs, especially for N2 diagnosis. However, there were some limitations, especially in cases with elevated peripheral WBC count and/or smoking history.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22290887     DOI: 10.1093/ejcts/ezr287

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer.

Authors:  David E Smith; Julian Fernandez Aramburu; Alejandro Da Lozzo; Juan A Montagne; Enrique Beveraggi; Agustin Dietrich
Journal:  Updates Surg       Date:  2019-09-24

2.  Evaluation of lobar lymph node metastasis in non-small cell lung carcinoma using modified total lesion glycolysis.

Authors:  Hitoshi Dejima; Hiroaki Kuroda; Yuko Oya; Noriaki Sakakura; Yoshitaka Inaba; Tsuneo Tamaki; Yasushi Yatabe; Yukinori Sakao
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

3.  Effects of fluctuating glucose levels on neuronal cells in vitro.

Authors:  Vincenzo C Russo; Sandra Higgins; George A Werther; Fergus J Cameron
Journal:  Neurochem Res       Date:  2012-05-08       Impact factor: 3.996

4.  Usefulness of positron-emission tomography for predicting the World Health Organization grade of thymic epithelial tumors.

Authors:  Takashi Kanou; Soichiro Funaki; Masato Minami; Naoko Ose; Toru Kimura; Eriko Fukui; Tadashi Watabe; Yasushi Shintani
Journal:  Thorac Cancer       Date:  2022-04-22       Impact factor: 3.223

5.  A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT.

Authors:  Kyoungjune Pak; Keunyoung Kim; Mi-Hyun Kim; Jung Seop Eom; Min Ki Lee; Jeong Su Cho; Yun Seong Kim; Bum Soo Kim; Seong Jang Kim; In Joo Kim
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240

Review 6.  18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.

Authors:  Yusuke Takahashi; Shigeki Suzuki; Noriyuki Matsutani; Masafumi Kawamura
Journal:  Thorac Cancer       Date:  2019-01-21       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.